| review article | Q7318358 |
| scholarly article | Q13442814 |
| evaluation study | Q58898636 |
| P2093 | author name string | Karen King | |
| Quincy Chu | |||
| Andrew Scarfe | |||
| Karen Mulder | |||
| Jennifer Spratlin | |||
| Sheryl Koski | |||
| P2860 | cites work | The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 |
| Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma | Q73708804 | ||
| Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery | Q74492639 | ||
| Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma | Q74595261 | ||
| Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation | Q74614669 | ||
| Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice | Q77132931 | ||
| Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma | Q77411244 | ||
| Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas | Q78204868 | ||
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
| Advances in the treatment of metastatic colorectal cancer | Q82040616 | ||
| VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 | ||
| Analysis of mortality rates for pancreatic cancer across the world | Q24646766 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Vascular endothelial growth factor is a secreted angiogenic mitogen | Q28646475 | ||
| Angiogenesis in cancer, vascular, rheumatoid and other disease | Q29547165 | ||
| Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Angiogenesis in life, disease and medicine | Q29614539 | ||
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| Vascular endothelial growth factor (VEGF) and its receptors | Q29615390 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy | Q30790872 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor | Q33241590 | ||
| Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study | Q33384665 | ||
| Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study | Q33385313 | ||
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Q33389519 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial | Q33620083 | ||
| Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. | Q33627763 | ||
| VEGFs, receptors and angiogenesis | Q33644265 | ||
| Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. | Q33710574 | ||
| Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | Q33747394 | ||
| Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. | Q33990928 | ||
| Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). | Q34049260 | ||
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. | Q34166741 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors | Q34414237 | ||
| Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. | Q34525788 | ||
| Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Q34530109 | ||
| Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts | Q47594304 | ||
| Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. | Q47826371 | ||
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. | Q51776237 | ||
| De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. | Q52968592 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis | Q55482573 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Prognostic value of vascular endothelial growth factor expression in gastric carcinoma | Q71018131 | ||
| Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor | Q71048188 | ||
| Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms | Q71656434 | ||
| Vascular endothelial growth factor and its receptors | Q71910454 | ||
| Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 | ||
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. | Q34557866 | ||
| Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma | Q34566598 | ||
| Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study | Q34583973 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma | Q34593345 | ||
| Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Biliary tract cancers: current concepts and controversies | Q36066076 | ||
| Fibroblast growth factor signaling in tumorigenesis | Q36111404 | ||
| ZD6474--clinical experience to date | Q36146882 | ||
| VEGF as a therapeutic target in cancer | Q36319029 | ||
| Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients | Q36422753 | ||
| Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study | Q36474101 | ||
| Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. | Q36476765 | ||
| Serum concentrations of vascular endothelial growth factor and nitrite as an estimate of in vivo nitric oxide in patients with gastric cancer | Q36620463 | ||
| The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer | Q37028542 | ||
| Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? | Q37672822 | ||
| Ramucirumab (IMC-1121B): a novel attack on angiogenesis. | Q37771954 | ||
| Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo | Q38302219 | ||
| FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival | Q38438387 | ||
| Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer | Q38480006 | ||
| Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer | Q40211792 | ||
| High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies | Q40227356 | ||
| ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model | Q40391647 | ||
| VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment | Q40725945 | ||
| Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer | Q41705602 | ||
| Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. | Q42830363 | ||
| Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study | Q43237133 | ||
| Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies | Q43282879 | ||
| Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants | Q43509136 | ||
| Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases | Q43845123 | ||
| Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. | Q43945228 | ||
| VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis | Q44043154 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice | Q44183328 | ||
| Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas | Q44660500 | ||
| ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. | Q45059139 | ||
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer | Q45106840 | ||
| Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study | Q46138295 | ||
| Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer | Q46252282 | ||
| Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors | Q46499714 | ||
| Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer | Q46781781 | ||
| P275 | copyright license | Creative Commons Attribution 2.5 Generic | Q18810333 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| medical oncology | Q6050805 | ||
| carcinoma | Q33525 | ||
| gastrointestinal neoplasm | Q58833942 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 515-529 | |
| P577 | publication date | 2010-11-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future | |
| P478 | volume | 1 |
| Q39117804 | Blockade of the PDGFR family together with SRC leads to diminished proliferation of colorectal cancer cells. |
| Q36739034 | Loss of 11βHSD1 enhances glycolysis, facilitates intrahepatic metastasis, and indicates poor prognosis in hepatocellular carcinoma |
| Q39042983 | Pancreatic-carcinoma-cell-derived pro-angiogenic factors can induce endothelial-cell differentiation of a subset of circulating CD34+ progenitors. |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q35740782 | Recent progress in targeting cancer |
| Q35176443 | Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy |
| Q33688390 | Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. |
Search more.